Genetics of severe drug hypersensitivity reactions in Han Chinese

Drug Hypersensitivity

Volumn , Issue , 2007, Pages 105-114

  Hung, Shuen Iu ^a   Chen Dr , Yuan Tsong ^a   Chung, Wen Hung ^a,b  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882174796     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000104194     Document Type: Chapter

References (30)

1. Pirmohamed M, Naisbitt DJ, Gordon F, Park BK: The danger hypothesis -potential role in idiosyncratic drug reactions. Toxicology 2002; 181-182:55-63
2. Fischer PR, Shigeoka AO: Familial occurrence of Stevens-Johnson syndrome. Am J Dis Child 1983;137:914-916
3. Johnson-Reagan L, Bahna SL: Severe drug rashes in three siblings simulta-neously. Allergy 2003;58:445-447.
4. Pritchett JH, Austin AC: Stevens-John-son syndrome occurring in identical twins with apparent response to terra-mycin and aureomycin. J Med Assoc Ga 1951;40:374-376.
5. Edwards SG, Hubbard V, Aylett S, Wren D: Concordance of primary generalised epilepsy and carbamazepine hypersen-sitivity in monozygotic twins. Postgrad Med J 1999;75:680-681.
6. Roujeau JC, Stern RS: Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-1285.
7. Rzany B, Mockenhaupt M, Baur S,Schroder W, Stocker U, Mueller J, Hol-lander N, Bruppacher R, Schopf E: Epi-demiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrol-ysis in Germany (1990-1992): struc-ture and results of a population-based registry. J Clin Epidemiol 1996;49:769-773.
8. Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, Walker AM: The inci-dence of erythema multiforme, Ste-vens-Johnson syndrome, and toxic epi-dermal necrolysis. A population-based study with particular reference to reac-tions caused by drugs among outpa-tients. Arch Dermatol 1990;126:43-47.
9. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT: Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486.
10. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bas-tuji-Garin S, Correia O, Locati F, Mock-enhaupt M, Paoletti C, Shapiro S, Shear N, Schöpf E, Kaufman DW: Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necroly-sis. N Engl J Med 1995;333:1600-1607.
11. Hung SI, Chung WH, Chen YT: HLA-B genotyping to detect carbamazepine-induced Stevens-Johnson syndrome: implications for personalizing medi-cine. Personalized Med 2005;2:225-237.
12. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopuri-nol. Proc Natl Acad Sci USA 2005;102:4134-4139.
13. Pan WH, Fann CS, Wu JY, Hung YT, Ho MS, Tai TH, Chen YJ, Liao CJ, Yang ML, Cheng AT, Chen YT: Han Chinese cell and genome bank in Taiwan: pur-pose, design and ethical consider-ations. Hum Hered 2006;61:27-30.
14. Yang HC, Lin CH, Hsu CL, Hung SI, Wu JY, Pan WH, Chen YT, Fann CS: A com-parison of major histocompatibility complex SNPs in Han Chinese residing in Taiwan and Caucasians. J Biomed Sci 2006;13:489-498.
15. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW, Hsiao PF, Chen WH, Shih HY, Fang WH, Wei CY, Lou YH, Huang YL, Lin JJ, Chen YT: Genet-ic susceptibility to carbamazepine-induced cutaneous adverse drug reac-tions. Pharmacogenet Genomics 2006;16:297-306.
16. Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P, Bagot M, Roujeau JC: Toxic epidermal necrolysis: effector cells are drug-spe-cific cytotoxic T cells. J Allergy Clin Immunol 2004;114:1209-1215.
17. Naisbitt DJ, Britschgi M, Wong G, Far-rell J, Depta JP, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK: Hyper-sensitivity reactions to carbamazepine: characterization of the specificity, phe-notype, and cytokine profile of drug-specific T-cell clones. Mol Pharmacol 2003;63:732-741.
18. Hung SI, Chung WH, Fang WH, Ou Yang CW, Chen CH, Fann CS, Wu JY, Chen YT: Genome-wide scan for genet-ic markers associated with carbamaze-pine-and allopurinol-induced severe cutaneous adverse reactions. 2nd Inter-national Drug Hypersensitivity Meet-ing, Liverpool, April 18-21, 2006, ab-stract 53.
19. Martin AM, Nolan D, Gaudieri S, Al-meida CA, Nolan R, James I, Carvalho F, Phillips E, Christiansen FT, Purcell AW, McCluskey J, Mallal S: Predisposi-tion to abacavir hypersensitivity con-ferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004;101:4180-4185.
20. Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, Graf E, Schumacher M, Hovnanian A, Mock-enhaupt M, Roujeau JC; RegiSCAR Group: A marker for Stevens-Johnson syndrome...: ethnicity matters. Phar-macogenomics J 2006;6:265-268.
21. Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH, Nangle K, Scott T, Spreen WR, Warren LL, Roses AD; CNA30027 Study Team; CNA30032 Study Team: Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharma-cogenomics 2004;5:203-211.
22. Daar AS, Singer PA: Pharmacogenetics and geographical ancestry: implica-tions for drug development and global health. Nat Rev Genet 2005;6:241-246.
23. Wilson JF, Weale ME, Smith AC, Gra-trix F, Fletcher B, Thomas MG, Brad-man N, Goldstein DB: Population ge-netic structure of variable drug response. Nat Genet 2001;29:265-269.
24. Website: Allele Frequencies (http://www.allelefrequencies.net/).
25. Dainachi T: Common HLA allele pre-sented in the case of Stevens-Johnson syndrome and drug-induced hypersen-sitivity syndrome by allopurinol. 7th International Congress on Cutaneous Adverse Drug Reactions, Paris, Sep-tember 6, 2006, abstract 608.
26. Lonjou C: A European genetic study of Stevens-Johnson syndrome and toxic epidermal necrolysis: HLA-B associa-tions with specific high-risk drugs. 7th International Congress on Cutaneous Adverse Drug Reactions, Paris, Sep-tember 6, 2006, abstract 207.
27. Schlosstein L, Terasaki PI, Bluestone R, Pearson CM: High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 1973;288:704-706.
28. Pirmohamed M, Lin K, Chadwick D, Park BK: TNF promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology 2001;56:890-896.
29. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmo-hamed M: HLA-B locus in Caucasian patients with carbamazepine hypersen-sitivity. Pharmacogenomics 2006;7:813-818.
30. Chan SH, Tan T: HLA and allopurinol drug eruption. Dermatologica 1989;179:32-33.